Heart failure (HF) is a complex clinical condition resulting from any structural and functional heart disease that leads to the inability to fill the chambers of the heart or move blood forward. Congenital heart disease (CHD) is the most important cause of chronic heart failure (CHF) in children.

heart, blood vessels, medicines.

Heart failure in pediatric patients with congenital heart disease. Hinton RB, Ware SM. Circ Res. 2017;120:978–994.

Beta-blockers for congestive heart failure in children. Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y. Cochrane Database Syst Rev. 2020;7:0.

Medical management of pediatric heart failure. Ahmed H, VanderPluym C. Cardiovasc Diagn Ther. 2021;11:323–335.

Epidemiology of congestive heart failure. Smith WM. Am J Cardiol. 1985;55:3–8. [PubMed] [Google Scholar]

Pediatric heart failure: a practical guide to diagnosis and management. Masarone D, Valente F, Rubino M, et al. https://doi.org/10.1016/j.pedneo.2017.01.001. Pediatr Neonatol. 2017;58:303–312. [PubMed] [Google Scholar]

Acute heart failure. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, Mebazaa A. Nat Rev Dis Primers. 2020;6:16.

Sacubitril/Valsartan: neprilysin iInhibition 5 years aAfter PARADIGM-HF. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJ. JACC Heart Fail. 2020;8:800–810.

Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Hanna A, Frangogiannis NG. Cardiovasc Drugs Ther. 2020;34:849–863.

Drug layering in heart failure: phenotype-guided initiation. Rosano GM, Allen LA, Abdin A, et al. JACC Heart Fail. 2021;9:775–783.

Current and future drug and device therapies for pediatric heart failure patients: potential lessons from adult trials. Das BB, Moskowitz WB, Butler J. Children (Basel) 2021;8:322.

Current state of pediatric heart failure. Das BB. Children (Basel) 2018;5:88. [PMC free article] [PubMed] [Google Scholar]

Pediatric heart failure therapy: why β1-receptor blocker, tissue ACE-I and mineralocorticoid-receptor-blocker? Recla S, Schmidt D, Logeswaran T, Esmaeili A, Schranz D. Transl Pediatr. 2019;8:127–132.

Angiotensin-converting enzyme inhibitors. Brown NJ, Vaughan DE. Circulation. 1998;97:1411–1420.

Are we misunderstanding beta-blockers. Cruickshank JM. Int J Cardiol. 2007;120:10–27.

Inverse agonism and its therapeutic significance. Khilnani G, Khilnani AK. Indian J Pharmacol. 2011;43:492–501.

Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1) Somasekharan S, Tanis J, Forbush B. J Biol Chem. 2012;287:17308–17317.

Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Delpire E, Lu J, England R, Dull C, Thorne T. Nat Genet. 1999;22:192–195.

Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Oppermann M, Hansen PB, Castrop H, Schnermann J. Am J Physiol Renal Physiol. 2007;293:0–87.

Contribution of the basolateral isoform of the Na-K-2Cl- cotransporter (NKCC1/BSC2) to renin secretion. Castrop H, Lorenz JN, Hansen PB, et al. Am J Physiol Renal Physiol. 2005;289:0–92.

Diuretic treatment in heart failure. Ellison DH, Felker GM. N Engl J Med. 2017;377:1964–1975.

Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Circulation. 2016;134:752–772.